Ann: Experienced Pharma Executive Joins Prescient Board, page-2

This appointment of Dr Ellen Feigal speaks volumes as to what is being planned ahead for Prescient.

Clearly Steven is very confident that we are going to be working on commercial contracts etc etc.

"Her deep operational understanding of cancer therapy regulatory pathways, manufacturing and markets will be invaluable as Prescient approaches a clinical inflexion point for PTX-100 and progresses its next-generation cancer therapy platforms, OmniCAR and CellPryme.”

Dr Feigal added, “I am excited to join the board of Prescient at this critical phase in the Company’s journey. I look forward to working with the team to leverage my experience and networks to guide the business through the next phase of its growth, in particular the formative stage of clinical development of PTX-100 and the development of its novel cell therapy platforms within this burgeoning and rapidly evolving field.”